Literature DB >> 32635549

Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification.

Chengbiao Chu1,2, Kai Yao1,3, Jiangli Lu1,2, Yijun Zhang1,2, Keming Chen1,2, Jiabin Lu1,2, Chris Zhiyi Zhang4, Yun Cao1,2.   

Abstract

The tumor immune microenvironment (TIME) plays an important role in penile squamous cell carcinoma (peSCC) pathogenesis. Here, the immunophenotype of the TIME in peSCC was determined by integrating the expression patterns of immune checkpoints (programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and Siglec-15) and the components of tumor-infiltrating lymphocytes, including CD8+ or Granzyme B+ T cells, FOXP3+ regulatory T cells, and CD68+ or CD206+ macrophages, in 178 patients. A high density of Granzyme B, FOXP3, CD68, CD206, PD-1, and CTLA-4 was associated with better disease-specific survival (DSS). The patients with diffuse PD-L1 tumor cell expression had worse prognoses than those with marginal or negative PD-L1 expression. Four immunophenotypes were identified by unsupervised clustering analysis, based on certain immune markers, which were associated with DSS and lymph node metastasis (LNM) in peSCC. There was no significant relationship between the immunophenotypes and high-risk human papillomavirus (hrHPV) infection. However, the hrHPV-positive peSCC exhibited a higher density of stromal Granzyme B and intratumoral PD-1 than the hrHPV-negative tumors (p = 0.049 and 0.002, respectively). In conclusion, the immunophenotypes of peSCC were of great value in predicting LNM and prognosis, and may provide support for clinical stratification management and immunotherapy intervention.

Entities:  

Keywords:  CTLA-4; HPV; PD-L1; Siglec-15; peSCC; prognosis; tumor immune microenvironment

Year:  2020        PMID: 32635549     DOI: 10.3390/cancers12071796

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

2.  Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma-A Report of Two Cases.

Authors:  Xinkuan Mei; Yanyan Zhao; Yiruo Zhang; Jinhua Liao; Chen Jiang; Hesheng Qian; Yingying Du
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

3.  The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.

Authors:  T Müller; M Demes; A Lehn; J Köllermann; S Vallo; P J Wild; R Winkelmann
Journal:  Clin Transl Oncol       Date:  2021-08-27       Impact factor: 3.405

Review 4.  Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.

Authors:  Tynisha S Rafael; Jossie Rotman; Oscar R Brouwer; Henk G van der Poel; Constantijne H Mom; Gemma G Kenter; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

5.  Identification of an m6A Regulators-Mediated Prognosis Signature For Survival Prediction and Its Relevance to Immune Infiltration in Melanoma.

Authors:  Liuxing Wu; Xin Hu; Hongji Dai; Kexin Chen; Ben Liu
Journal:  Front Cell Dev Biol       Date:  2021-11-25

6.  Integrated Analysis of Multiomics Data Identified Molecular Subtypes and Oxidative Stress-Related Prognostic Biomarkers in Glioblastoma Multiforme.

Authors:  Yawen Ma; Zhuo Xi
Journal:  Oxid Med Cell Longev       Date:  2022-09-22       Impact factor: 7.310

7.  Equine Penile Squamous Cell Carcinomas as a Model for Human Disease: A Preliminary Investigation on Tumor Immune Microenvironment.

Authors:  Ilaria Porcellato; Samanta Mecocci; Luca Mechelli; Katia Cappelli; Chiara Brachelente; Marco Pepe; Margherita Orlandi; Rodolfo Gialletti; Benedetta Passeri; Angelo Ferrari; Paola Modesto; Alessandro Ghelardi; Elisabetta Razzuoli
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.